Background: Esophageal cancer is a public health concern around the world; this cancer is the sixth leading cause of death of cancer in the world with about 386,000 deaths per year. Its risk factors include environmental factors such as tobacco smoke, gastroesophageal reflux and genetic changes. iNOS is stated by the effect of various inflammatory factors and is thus called inducible NOS. Investigating iNOS expression is a powerful tool for understanding effective molecular parameters at tissue and cellular responses to external factors. In this research work, iNOS expression in patients with esophageal cancer was studied in Iran. Materials and Methods: 15 formalin-fixed and paraffin-embedded (FFPE) esophageal cancer tissue samples and 15 normal FFPE samples were collected from various medical centers (Zabol, Zahedan, Kashan) to measure iNOS expression by real-time reverse transcriptase polymerase chain reaction (real-time RT-PCR). All PCR reactions were conducted by three replicates for iNOS and internal control (β-actin) by 2-ΔΔCT (Livak) method. Differences were measured in target gene expression in patients and control group using the t test. All statistical analyses were done using the SPSS software. Results: The results showed that there was no significant difference between iNOS expression in the case and control groups (p > 0.05); however, there was an increase in iNOS expression in the case group. On the other hand, there was a significant difference between iNOS expression in males and females in the two groups of healthy subjects and patients, and it was higher in women than in men. Conclusion: Further studies need to be conducted with larger sample sizes and in other populations to validate these findings.

Keywords:
Esophageal cancer, iNOS, Quantitative real-time reverse transcriptase polymerase chain reaction
1.
Motalleb G, Gholipour N, Samaei NM: Association of the human astrocyte elevated gene-1 promoter variants with susceptibility to hepatocellular carcinoma. Med Oncol 2014;31:916.
2.
Blot WJ: Esophageal cancer trends and risk factors. Semin Oncol 1994;21:403-410.
3.
Ribeiro U Jr, Posner MC, Safatle-Ribeiro AV, Reynolds JC: Risk factors for squamous cell carcinoma of the oesophagus. Br J Surg 1996;83:1174-1185.
4.
Knowles RG, Moncada S: Nitric oxide synthases in mammals. Biochem J 1994;298:249-258.
5.
Ignarro LJ, Buga GM, Wood KS, Byrns RE, Chaudhuri G: Endothelium-derived relaxing factor produced and released from artery and vein is nitric oxide. Proc Natl Acad Sci USA 1987;84:9265-9269.
6.
Palmer RM, Ferrige AG, Moncada S: Nitric oxide release accounts for the biological activity of endothelium-derived relaxing factor. Nature 1987;327:524-526.
7.
Scott DJ, Hull MA, Cartwright EJ, Lam WK, Tisbury A, Poulsom R, Markham AF, Bonifer C, Coletta PL: Lack of inducible nitric oxide synthase promotes intestinal tumorigenesis in the Apc(Min/+) mouse. Gastroenterology 2001;121:889-899.
8.
Moncada S, Palmer RMJ, Higgs EA: Nitric oxide: physiology, pathophysiology, and pharmacology. Pharmacol Rev 1991;43:109-142.
9.
Nathan C, Xie QW: Regulation of biosynthesis of nitric oxide. J Biol Chem 1994;269:13725-13728.
10.
Yagihashi N, Kasajima H, Sugai S, Matsumoto K, Ebina Y, Morita T, Murakami T, Yagihashi S: Increased in situ expression of nitric oxide synthase in human colorectal cancer. Virchows Arch 2000;436:109-114.
11.
Vakkala M, Kahlos K, Lakari E, Paakko P, Kinnula V, Soini Y: Inducible nitric oxide synthase expression, apoptosis, and angiogenesis in in situ and invasive breast carcinomas. Clin Cancer Res 2000;6:2408-2416.
12.
Wolf H, Haeckel C, Roessner A: Inducible nitric oxide synthase expression in human urinary bladder cancer. Virchows Arch 2000;437:662-666.
13.
Thomsen LL, Miles DW, Happerfield L, Bobrow LG, Knowles RG, Moncada S: Nitric oxide synthase activity in human breast cancer. Br J Cancer 1995;72:41-44.
14.
Aaltomaa SH, Lipponen PK, Viitanen J, Kankkunen JP, Ala-Opas MY, Kosma VM: The prognostic value of inducible nitric oxide synthase in local prostate cancer. BJU Int 2000;86:234-239.
15.
Abramovitz M, Ordanic-Kodani M, Wang Y, Li Z, Catzavelos C, Bouzyk M, Sledge GW Jr, Moreno CS, Leyland-Jones B: Optimization of RNA extraction from FFPE tissues for expression profiling in the DASL assay. Biotechniques 2008;44:417-423.
16.
Taherian A, Mostafavi Zadeh SM, Ghani H, Khamechian T: ST6Gal1, Cox-2 and HB-EGF mRNA expression in breast cancer samples from Kashan, Iran. Middle East J Cancer 2015;6:43-50.
17.
Soleimani M, Zolfaghari MR, Morovvati A: Development and comparison of conventional PCR and SYBR green real time PCR for detection of Aggregatibacter actinomycetemcomitans and Tannerella forsythensis. Jundishapur J Microbiol 2013;6:e6757.
18.
Pfaffl MW, Hageleit M: Validities of mRNA quantification using recombinant RNA and recombinant DNA external calibration curves in real-time RT-PCR. Biotechnol Lett 2001;23:275-282.
19.
Morse DL, Carroll D, Weberg L, Borgstrom MC, Ranger-Moore J, Gillies RJ: Determining suitable internal standards for mRNA quantification of increasing cancer progression in human breast cells by real-time reverse transcriptase polymerase chain reaction. Anal Biochem 2005;342:69-77.
20.
Livak KJ, Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2-ΔΔCT method. Methods 2001;25:402-408.
21.
Jemal A, Murray T, Samuels A, Ghafoor A, Ward E, Thun MJ: Cancer statistics for Hispanics. CA Cancer J Clin 2003;53:5-26.
22.
Gal A, Wogan GN: Mutagenesis associated with nitric oxide production in transgenic SJL mice. Proc Natl Acad Sci USA 1996;93:15102-15107.
23.
Wink DA, Vodovotz Y, Laval J, Laval F, Dewhirst MW, Mitchell JB: The multifaceted roles of nitric oxide in cancer. Carcinogenesis 1998;19:711-721.
24.
Vakkala M, Paakko P, Soini Y: eNOS expression is associated with the estrogen and progesterone receptor status in invasive breast carcinoma. Int J Oncol 2000;17:667-671.
25.
McInnes IB, Leung BP, Field M, Wei XQ, Huang FP, Sturrock RD, Kinninmonth A, Weidner J, Mumford R, Liew FY: Production of nitric oxide in the synovial membrane of rheumatoid and osteoarthritis patients. J Exp Med 1996;184:1519-1524.
26.
Grabowski PS, Wright PK, van 't Hof RJ, Helfrich MH, Ohshima H, Ralston SH: Immunolocalization of inducible nitric oxide synthase in synovium and cartilage in rheumatoid arthritis and osteoarthritis. Br J Rheumatol 1997;36:651-655.
27.
Bagasra O, Michaels FH, Zheng YM, Bobroski LE, Spitsin SV, Fu ZF, Tawadros R, Koprowski H: Activation of the inducible form of nitric oxide synthase in the brains of patients with multiple sclerosis. Proc Natl Acad Sci USA 1995;92:12041-12045.
28.
Hamid Q, Springall DR, Riveros-Moreno V, Chanez P, Howarth P, Redington A, Bousquet J, Godard P, Holgate S, Polak JM: Induction of nitric oxide synthase in asthma. Lancet 1993;342:1510-1513.
29.
Kroncke KD, Kolb-Bachofen V, Berschick B, Burkart V, Kolb H: Activated macrophages kill pancreatic syngeneic islet cells via arginine-dependent nitric oxide generation. Biochem Biophys Res Commun 1991;175:752-758.
30.
Chen T, Rose ME, Hwang H, Nines RG, Stoner GD: Black raspberries inhibit N-nitrosomethylbenzylamine (NMBA)-induced angiogenesis in rat esophagus parallel to the suppression of COX-2 and iNOS. Carcinogenesis 2006;27:2301-2307.
31.
Jaiswal M, LaRusso NF, Gores GJ: Nitric oxide in gastrointestinal epithelial cell carcinogenesis: linking inflammation to oncogenesis. Am J Physiol Gastrointest Liver Physiol 2001;281:G626-G634.
32.
Lechner M, Lirk P, Rieder J: Inducible nitric oxide synthase (iNOS) in tumor biology: the two sides of the same coin. Semin Cancer Biol 2005;15:277-289.
33.
Wilson KT, Fu S, Ramanujam KS, Meltzer SJ: Increased expression of inducible nitric oxide synthase and cyclooxygenase-2 in Barrett's esophagus and associated adenocarcinomas. Cancer Res 1998;58:2929-2934.
34.
Schroder NW, Opitz B, Lamping N, Michelsen KS, Zahringer U, Gobel UB, Schumann RR: Involvement of lipopolysaccharide binding protein, CD14, and Toll-like receptors in the initiation of innate immune responses by Treponema glycolipids. J Immunol 2000;165:2683-2693.
35.
Du X, Low MG: Down-regulation of glycosylphosphatidylinositol-specific phospholipase D induced by lipopolysaccharide and oxidative stress in the murine monocyte-macrophage cell line RAW 264.7. Infect Immun 2001;69:3214-3223.
36.
Rao KM: Molecular mechanisms regulating iNOS expression in various cell types. J Toxicol Environ Health B Crit Rev 2000;3:27-58.
37.
Aktan F: iNOS-mediated nitric oxide production and its regulation. Life Sci 2004;75:639-653.
38.
Jungi TW, Adler H, Adler B, Thony M, Krampe M, Peterhans E: Inducible nitric oxide synthase of macrophages. Present knowledge and evidence for species-specific regulation. Vet Immunol Immunopathol 1996;54:323-330.
39.
Lahti A, Kankaanranta H, Moilanen E: p38 mitogen-activated protein kinase inhibitor SB203580 has a bi-directional effect on iNOS expression and NO production. Eur J Pharmacol 2002;454:115-123.
40.
Marks-Konczalik J, Chu SC, Moss J: Cytokine-mediated transcriptional induction of the human inducible nitric oxide synthase gene requires both activator protein 1 and nuclear factor kappaB-binding sites. J Biol Chem 1998;273:22201-22208.
41.
Momose I, Terashima M, Nakashima Y, Sakamoto M, Ishino H, Nabika T, Hosokawa Y, Tanigawa Y: Phorbol ester synergistically increases interferon regulatory factor-1 and inducible nitric oxide synthase induction in interferon-gamma-treated RAW 264.7 cells. Biochim Biophys Acta 2000;1498:19-31.
42.
Muller MR, Pfannes SD, Ayoub M, Hoffmann P, Bessler WG, Mittenbuhler K: Immunostimulation by the synthetic lipopeptide P3CSK4: TLR4-independent activation of the ERK1/2 signal transduction pathway in macrophages. Immunology 2001;103:49-60.
43.
Wang BS, Lin JK, Lin-Shiau SY: Role of tyrosine kinase activity in 2,2′,2′′-tripyridine-induced nitric oxide generation in macrophages. Biochem Pharmacol 1999;57:1367-1373.
44.
Hecker M, Cattaruzza M, Wagner AH: Regulation of inducible nitric oxide synthase gene expression in vascular smooth muscle cells. Gen Pharmacol 1999;32:9-16.
45.
Kleinert H, Euchenhofer C, Ihrig-Biedert I, Forstermann U: In murine 3T3 fibroblasts, different second messenger pathways resulting in the induction of NO synthase II (iNOS) converge in the activation of transcription factor NF-kappaB. J Biol Chem 1996;271:6039-6044.
46.
Kleinert H, Wallerath T, Fritz G, Ihrig-Biedert I, Rodriguez-Pascual F, Geller DA, Forstermann U: Cytokine induction of NO synthase II in human DLD-1 cells: roles of the JAK-STAT, AP-1 and NF-kappaB-signaling pathways. Br J Pharmacol 1998;125:193-201.
47.
Xia YF, Liu LP, Zhong CP, Geng JG: NF-kappaB activation for constitutive expression of VCAM-1 and ICAM-1 on B lymphocytes and plasma cells. Biochem Biophys Res Commun 2001;289:851-856.
48.
Huang KT, Kuo L, Liao JC: Lipopolysaccharide activates endothelial nitric oxide synthase through protein tyrosine kinase. Biochem Biophys Res Commun 1998;245:33-37.
49.
Obermeier F, Gross V, Scholmerich J, Falk W: Interleukin-1 production by mouse macrophages is regulated in a feedback fashion by nitric oxide. J Leukoc Biol 1999;66:829-836.
50.
Ye X, Liu SF: Lipopolysaccharide regulates constitutive and inducible transcription factor activities differentially in vivo in the rat. Biochem Biophys Res Commun 2001;288:927-932.
51.
Aktan F, Henness S, Roufogalis BD, Ammit AJ: Gypenosides derived from Gynostemma pentaphyllum suppress NO synthesis in murine macrophages by inhibiting iNOS enzymatic activity and attenuating NF-kappaB-mediated iNOS protein expression. Nitric Oxide 2003;8:235-242.
52.
Bowie A, O'Neill LA: Oxidative stress and nuclear factor-kappaB activation: a reassessment of the evidence in the light of recent discoveries. Biochem Pharmacol 2000;59:13-23.
53.
Musial A, Eissa NT: Inducible nitric-oxide synthase is regulated by the proteasome degradation pathway. J Biol Chem 2001;276:24268-24273.
54.
Hecker M, Preiss C, Schini-Kerth VB: Induction by staurosporine of nitric oxide synthase expression in vascular smooth muscle cells: role of NF-kappa B, CREB and C/EBP beta. Br J Pharmacol 1997;120:1067-1074.
55.
Chong MM, Thomas HE, Kay TW: Suppressor of cytokine signaling-1 regulates the sensitivity of pancreatic beta cells to tumor necrosis factor. J Biol Chem 2002;277:27945-27952.
56.
Connelly L, Palacios-Callender M, Ameixa C, Moncada S, Hobbs AJ: Biphasic regulation of NF-kappa B activity underlies the pro-and anti-inflammatory actions of nitric oxide. J Immunol 2001;166:3873-3881.
57.
Perez-Sala D, Cernuda-Morollon E, Diaz-Cazorla M, Rodriguez-Pascual F, Lamas S: Posttranscriptional regulation of human iNOS by the NO/cGMP pathway. Am J Physiol Renal Physiol 2001;280:F466-F473.
58.
Lee SK, Kim JH, Yang WS, Kim SB, Park SK, Park JS: Exogenous nitric oxide inhibits VCAM-1 expression in human peritoneal mesothelial cells. Role of cyclic GMP and NF-kappaB. Nephron 2002;90:447-454.
59.
Han YJ, Kwon YG, Chung HT, Lee SK, Simmons RL, Billiar TR, Kim YM: Antioxidant enzymes suppress nitric oxide production through the inhibition of NF-kappa B activation: role of H2O2 and nitric oxide in inducible nitric oxide synthase expression in macrophages. Nitric Oxide 2001;5:504-513.
60.
Leceta J, Gomariz RP, Martinez C, Abad C, Ganea D, Delgado M: Receptors and transcriptional factors involved in the anti-inflammatory activity of VIP and PACAP. Ann NY Acad Sci 2000;921:92-102.
61.
Chinetti G, Griglio S, Antonucci M, Torra IP, Delerive P, Majd Z, Fruchart JC, Chapman J, Najib J, Staels B: Activation of proliferator-activated receptors alpha and gamma induces apoptosis of human monocyte-derived macrophages. J Biol Chem 1998;273:25573-25580.
62.
Rodriguez-Pascual F, Hausding M, Ihrig-Biedert I, Furneaux H, Levy AP, Forstermann U, Kleinert H: Complex contribution of the 3′-untranslated region to the expressional regulation of the human inducible nitric-oxide synthase gene. Involvement of the RNA-binding protein HuR. J Biol Chem 2000;275:26040-26049.
63.
Taylor BS, de Vera ME, Ganster RW, Wang Q, Shapiro RA, Morris SM Jr, Billiar TR, Geller DA: Multiple NF-kappaB enhancer elements regulate cytokine induction of the human inducible nitric oxide synthase gene. J Biol Chem 1998;273:15148-15156.
64.
Perrella MA, Yoshizumi M, Fen Z, Tsai JC, Hsieh CM, Kourembanas S, Lee ME: Transforming growth factor-beta 1, but not dexamethasone, down-regulates nitric-oxide synthase mRNA after its induction by interleukin-1 beta in rat smooth muscle cells. J Biol Chem 1994;269:14595-14600.
65.
Vodovotz Y: Control of nitric oxide production by transforming growth factor-beta1: mechanistic insights and potential relevance to human disease. Nitric Oxide 1997;1:3-17.
66.
Carpenter L, Cordery D, Biden TJ: Protein kinase Cdelta activation by interleukin-1beta stabilizes inducible nitric-oxide synthase mRNA in pancreatic beta-cells. J Biol Chem 2001;276:5368-5374.
67.
Oddis CV, Simmons RL, Hattler BG, Finkel MS: cAMP enhances inducible nitric oxide synthase mRNA stability in cardiac myocytes. Am J Physiol 1995;269:H2044-H2050.
68.
Chen J, Yan Y, Li J, Ma Q, Stoner GD, Ye J, Huang C: Differential requirement of signal pathways for benzo[a]pyrene (B[a]P)-induced nitric oxide synthase (iNOS) in rat esophageal epithelial cells. Carcinogenesis 2005;26:1035-1043.
69.
Grivennikov SI, Greten FR, Karin M: Immunity, inflammation, and cancer. Cell 2010;140:883-899.
70.
Xu W, Lizhi L, Loizidou M, Ahmed M, Taylor I, Moncada S, Charles IG: Nitric oxide synthase in human breast cancer, a doubled-edged sword? Nitric Oxide 2002;6:490.
71.
Loeb KR, Loeb LA: Significance of multiple mutations in cancer. Carcinogenesis 2000;21:379-385.
© 2016 S. Karger AG, Basel
2016
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.